{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:08:43Z","timestamp":1760144923995,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Soonchunhyang University Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Interest in the oligometastatic prostate cancer (OMPC) is increasing, and various clinical studies have reported the benefits of metastasis-directed radiation therapy (MDRT) in OMPC. However, the recognition regarding the adopted definitions, methodologies of assessment, and therapeutic approaches is diverse among radiation oncologists. This study aims to evaluate the level of agreement for issues in OMPC among radiation oncologists. Methods: We generated 15 key questions (KQs) for OMPC relevant to definition, diagnosis, local therapies, and endpoints. Additionally, three clinical scenarios representing synchronous metastatic prostate cancer (mPC) (case 1), metachronous mPC with visceral metastasis (case 2), and metachronous mPC with castration-resistance and history of polymetastasis (case 3) were developed. The 15 KQs were adapted according to each scenario and transformed into 23 questions with 6\u20139 per scenario. The survey was distributed to 80 radiation oncologists throughout the Republic of Korea. Answer options with 0.0\u201329.9%, 30\u201349.9%, 50\u201369.9%, 70\u201379.9%, 80\u201389.9%, and 90\u2013100% agreements were considered as no, minimal, weak, moderate, strong, and near perfect agreement, respectively. Results: Forty-five candidates voluntarily participated in this study. Among 23 questions, near perfect (n = 4), strong (n = 3), or moderate (n = 2) agreements were shown in nine. For the case recognized as OMPC with agreements of 93% (case 1), near perfect agreements on the application of definitive radiation therapy (RT) for whole metastatic lesions were achieved. While \u226570% agreements regarding optimal dose-fractionation for metastasis-directed RT (MDRT) has not been achieved, stereotactic body RT (SBRT) is favored by clinicians with higher clinical volume. Conclusion: For the case recognized as OMPC, near perfect agreement for the application of definitive RT for whole metastatic lesions was reached. SBRT was more favored as a MDRT by clinicians with a higher clinical volume.<\/jats:p>","DOI":"10.3390\/curroncol31060245","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:29:47Z","timestamp":1717417787000},"page":"3239-3251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation Oncologists\u2019 Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group"],"prefix":"10.3390","volume":"31","author":[{"given":"Gyu Sang","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-9529","authenticated-orcid":false,"given":"Sunmin","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Seoul 15355, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-4588","authenticated-orcid":false,"given":"Chai Hong","family":"Rim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Seoul 15355, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Kyung","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4220-8171","authenticated-orcid":false,"given":"Ah Ram","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology\/Cyberknife Center, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul 04401, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Asan Medical Center, Ulsan University School of Medicine, Seoul 05505, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-8472","authenticated-orcid":false,"given":"Yong Chan","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eui Kyu","family":"Chie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4143\/crt.2022.329","article-title":"Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis","volume":"54","author":"Rim","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/EDBK_239041","article-title":"Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?","volume":"39","author":"Rao","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2020.07.004","article-title":"Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials","volume":"3","author":"Connor","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2018.11.050","article-title":"Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?","volume":"75","author":"Lohaus","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2019.06.011","article-title":"Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor","volume":"105","author":"Yoshida","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2019.07.010","article-title":"Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting","volume":"3","author":"Aluwini","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijrobp.2022.06.067","article-title":"Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO\/EORTC Nomenclature","volume":"114","author":"Nevens","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease","volume":"62","author":"Barbato","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.22465\/kjuo.2022.20.4.207","article-title":"An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer","volume":"20","author":"Hong","year":"2022","journal-title":"Korean J. Urol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Surcel, C., Kretschmer, A., Mirvald, C., Sinescu, I., Heidegger, I., and Tsaur, I. (2022). Molecular Mechanisms Related with Oligometastatic Prostate Cancer-Is It Just a Matter of Numbers?. Cancers, 14.","DOI":"10.3390\/cancers14030766"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_18","unstructured":"National Comprehensive CAncer Network (2022, February 25). Prostate Cancer (Version 1.2023). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Olson, R., Mathews, L., Liu, M., Schellenberg, D., Mou, B., Berrang, T., Harrow, S., Correa, R.J.M., Bhat, V., and Pai, H. (2020). Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06876-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy","volume":"76","author":"Pasquier","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","article-title":"Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences","volume":"28","author":"Ost","year":"2016","journal-title":"Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"De Bruycker, A., Spiessens, A., Dirix, P., Koutsouvelis, N., Semac, I., Liefhooghe, N., Gomez-Iturriaga, A., Everaerts, W., Otte, F., and Papachristofilou, A. (2020). PEACE V\u2014Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06911-4"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4143\/crt.2013.168","article-title":"Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors","volume":"46","author":"Park","year":"2014","journal-title":"Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3857\/roj.2022.00101","article-title":"Bone-only oligometastatic prostate cancer: Can SABR improve outcomes? A single-center experience","volume":"40","year":"2022","journal-title":"Radiat. Oncol. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13014-022-02010-9","article-title":"Variability of alpha\/beta ratios for prostate cancer with the fractionation schedule: Caution against using the linear-quadratic model for hypofractionated radiotherapy","volume":"17","author":"Cui","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13014-018-1182-z","article-title":"Long-term results and PSA kinetics after robotic SBRT for prostate cancer: Multicenter retrospective study in Korea (Korean radiation oncology group study 15-01)","volume":"13","author":"Park","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alongi, P., Laudicella, R., Lanzafame, H., Farolfi, A., Mapelli, P., Picchio, M., Burger, I.A., Iagaru, A., Minutoli, F., and Evangelista, L. (2022). PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. Cancers, 14.","DOI":"10.3390\/cancers14071770"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:52:51Z","timestamp":1760107971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["curroncol31060245"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31060245","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}